Toll-like receptors as therapeutic targets in cystic fibrosis.
dc.contributor.author | Greene, Catherine M | |
dc.contributor.author | Branagan, Peter | |
dc.contributor.author | McElvaney, Noel G | |
dc.date.accessioned | 2011-07-25T08:32:38Z | |
dc.date.available | 2011-07-25T08:32:38Z | |
dc.date.issued | 2008-12 | |
dc.identifier.citation | Toll-like receptors as therapeutic targets in cystic fibrosis. 2008, 12 (12):1481-95 Expert Opin. Ther. Targets | en |
dc.identifier.issn | 1744-7631 | |
dc.identifier.pmid | 19007318 | |
dc.identifier.doi | 10.1517/14728220802515293 | |
dc.identifier.uri | http://hdl.handle.net/10147/136766 | |
dc.description.abstract | Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular patterns in microbial factors and endogenous danger signals. Cystic fibrosis (CF)-affected airways represent a milieu potentially rich in TLR agonists and the chronic inflammatory phenotype evident in CF airway epithelial cells is probably due in large part to activation of TLRs. Objective/methods: To examine the prospects of developing novel therapies for CF by targeting TLRs. We outline the expression and function of TLRs and explore the therapeutic potential of naturally-occurring and synthetic TLR inhibitors for CF. Results/conclusion: Modulation of TLRs has therapeutic potential for the inflammatory lung manifestations of CF. | |
dc.language.iso | en | en |
dc.relation.url | http://www.ncbi.nlm.nih.gov/pubmed/19007318 | en |
dc.subject.mesh | Anti-Inflammatory Agents, Non-Steroidal | |
dc.subject.mesh | Cystic Fibrosis | |
dc.subject.mesh | Drug Design | |
dc.subject.mesh | Gene Expression Regulation | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Toll-Like Receptors | |
dc.title | Toll-like receptors as therapeutic targets in cystic fibrosis. | en |
dc.type | Article | en |
dc.contributor.department | Beaumont Hospital, Education and Research Centre, Respiratory Research Division, Royal College of Surgeons in Ireland, 9 Dublin, Ireland. cmgreene@rcsi.ie | en |
dc.identifier.journal | Expert opinion on therapeutic targets | en |
dc.description.province | Leinster | |
html.description.abstract | Background: Toll-like receptors (TLRs) are pattern recognition receptors that act as a first-line of defence in the innate immune response by recognising and responding to conserved molecular patterns in microbial factors and endogenous danger signals. Cystic fibrosis (CF)-affected airways represent a milieu potentially rich in TLR agonists and the chronic inflammatory phenotype evident in CF airway epithelial cells is probably due in large part to activation of TLRs. Objective/methods: To examine the prospects of developing novel therapies for CF by targeting TLRs. We outline the expression and function of TLRs and explore the therapeutic potential of naturally-occurring and synthetic TLR inhibitors for CF. Results/conclusion: Modulation of TLRs has therapeutic potential for the inflammatory lung manifestations of CF. |